AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

20.540

+0.1900.93%

Volume:39.27K

Turnover:800.19K

Market Cap:2.60B

PE:131.74

High:20.570

Open:20.070

Low:20.070

Close:20.350

52wk High:23.588

52wk Low:10.920

Shares:126.64M

Float Shares:108.39M

Volume Ratio:1.82

T/O Rate:0.04%

Dividend:0.15

Dividend Rate:0.73%

EPS(TTM):0.156

EPS(LYR):0.233

ROE:6.17%

ROA:2.58%

PB:7.80

PE(LYR):88.27

Loading ...

Overview Company News Filings

4DMedical And 2 Other Australian Growth Stocks To Own

Simply Wall St.

Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041

MT Newswires Live

Elite Australian Growth Stocks To Own In September 2026

Simply Wall St.

Neuren Pharmaceuticals (ASX:NEU) Reports Higher Sales And Interim Dividend, Is The Valuation Too Rich?

Simply Wall St.

NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus

Simply Wall St.

Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up

MT Newswires Live

Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million

THOMSON REUTERS

Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug

MT Newswires Live

Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)

THOMSON REUTERS

ASX Biggest Gainers

MT Newswires Live

Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties

Simply Wall St.

Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says

MT Newswires Live

Strong Partner Sales Propel Neuren Pharmaceuticals to Top of Australia Benchmark

Neuren Pharmaceuticals Limited-Record Q2 Daybue Net Sales of Us$125m, Cy26 Royalty Upgraded

THOMSON REUTERS

Earnings Flash (NEU) NewMarket Posts Q2 EPS of $14.54

MT Newswires Live

NewMarket (NEU) Stock Looks Cheap Despite Its 182% Five Year Run

Simply Wall St.

How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population Estimate

Simply Wall St.

Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%

Simply Wall St.

Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?

Simply Wall St.

Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NEU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":20.54,"timestamp":1790814147368,"preClose":20.35,"halted":0,"volume":39274,"delay":0,"changeRate":0.009336609336609224,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":0.155917,"marketStatus":"Trading","change":0.19,"latestTime":"10-01 10:22:27 AEST","open":20.07,"high":20.57,"low":20.07,"amount":800191,"amplitude":0.02457,"askPrice":20.54,"askSize":145,"bidPrice":20.51,"bidSize":140,"shortable":3,"etf":0,"ttmEps":0.155917,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790834400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":20.35,"dividendRate":0.007303,"openAndCloseTimeList":[[1790812800000,1790834400000]],"volumeRatio":1.821212,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NEU.AU","preClose":20.35,"auctionPrice":20.07,"auctionVolume":2983,"auctionTime":1790812742288,"referenceTime":1790764203089,"auction":1,"marketStatus":"盘前竞价","timestamp":1790812742288}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"2.58%","roe":"6.17%","lyrEps":0.2327,"volumeRatio":1.821212,"shares":126639526,"dividePrice":0.15,"high":20.57,"amplitude":0.02457,"preClose":20.35,"low":20.07,"week52Low":10.92,"pbRate":"7.80","psRate":"37.41","week52High":23.588,"institutionHeld":0,"latestPrice":20.54,"committee":-0.017544,"eps":0.155917,"divideRate":0.007303,"volume":39274,"delay":0,"ttmEps":0.155917,"open":20.07,"prevYearClose":18.475,"prevWeekClose":20.22,"prevMonthClose":20.35,"prevQuarterClose":20.35,"fiveDayClose":20.6,"twentyDayClose":20.421,"sixtyDayClose":16.658},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NEU.AU","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-16","defaultRemindTime":1789430400000,"name":"NEUREN PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-07","payableDate":"2026-09-16","currency":"AUD","dateTimestamp":1789394400000,"payDate":"2026-10-07"},{"date":"2026-08-26","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2026-09-15","recordDate":"2026-09-16","paymentDate":"2026-10-07","value":0.15,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671277550","title":"4DMedical And 2 Other Australian Growth Stocks To Own","url":"https://stock-news.laohu8.com/highlight/detail?id=2671277550","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671277550?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:21","pubTimestamp":1790724093,"startTime":"0","endTime":"0","summary":"Australia’s interest rate now sits at a 15 year high of 4.6%, which makes dependable earnings growth harder to find and more valuable when you do. Higher borrowing costs punish weak balance sheets, yet stronger businesses with solid finances and clear profit expansion stories can still build wealth. This article highlights three Australian high growth potential stocks from our healthy growth screen that fit that profile.\nThe three stocks covered below are a small sample, with the full healthy...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-and-2-other-australian-growth-stocks-to-own","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-and-2-other-australian-growth-stocks-to-own","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7503","DECU","SLF.AU","PMDE","VAP.AU","VAS.AU","IISV.AU","BK7508","GIVE.AU","BK7096","IOZ.AU","VOTE","XAO.AU","BK7094","FEBU","E200.AU","BK7043","VGFPF","ZYAU.AU","STW.AU","4DX.AU","OZF.AU","IMLC.AU","DACE.AU","NEU.AU","XKO.AU","GXDW","IIGF.AU","GEAR.AU","JOYT","RGLO","BEAR.AU","BBOZ.AU","QRE.AU","XJO.AU","QFN.AU","OZR.AU","MP1.AU","EIGA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671261940","title":"Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2671261940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671261940?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:25","pubTimestamp":1790645148,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said partner Acadia Pharmaceuticals received a notice of allowance from the US Patent and Trademark Office for a new US patent covering weight-banded dosing of trofinetide, according to a Tuesday Australian bourse filing.The patent, once issued and with six months of pediatric exclusivity, is expected to extend US patent protection for trofinetide to March 28, 2041, nearly five years beyond the current protection period, the filing said.Trofinetide is marketed in the US under the brand names Daybue and Daybue Stix for patients aged two years and older with Rett syndrome, the filing added.The company's shares rose 2% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","USRD","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670707554","title":"Elite Australian Growth Stocks To Own In September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2670707554","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670707554?lang=en_us&edition=fundamental","pubTime":"2026-09-26 11:28","pubTimestamp":1790393289,"startTime":"0","endTime":"0","summary":"Rising long term bond yields have pushed borrowing costs higher, which puts pressure on many growth stocks that rely heavily on cheap debt. That makes financially healthier Australian growth stories more interesting right now. This screener focuses on businesses where analysts see strong earnings growth potential and balance sheets that can better handle higher rates. In this article, you will see three of the strongest candidates from that group.\nThe three Australian stocks highlighted below...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/elite-australian-growth-stocks-to-own-in-september-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/elite-australian-growth-stocks-to-own-in-september-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["4DX.AU","CHAT","QRE.AU","AIPO","ARTY","BBOZ.AU","EIGA.AU","BK7094","QTOC","IIGF.AU","IOZ.AU","BEAR.AU","ZYAU.AU","IMLC.AU","MP1.AU","AGIX","BK7096","OZR.AU","SLF.AU","XJO.AU","VTHR","XKO.AU","DACE.AU","IISV.AU","GEAR.AU","E200.AU","NEU.AU","OZF.AU","XAO.AU","GIVE.AU","BK7503","BK7508","QFN.AU","BK7043","VAS.AU","VAP.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664280868","title":"Neuren Pharmaceuticals (ASX:NEU) Reports Higher Sales And Interim Dividend, Is The Valuation Too Rich?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664280868","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664280868?lang=en_us&edition=fundamental","pubTime":"2026-09-02 00:27","pubTimestamp":1788280022,"startTime":"0","endTime":"0","summary":"Why Neuren Pharmaceuticals stock is in focus now\nNeuren Pharmaceuticals (ASX:NEU) has caught investor attention after reporting half year 2026 results showing higher sales and revenue, a lower net profit figure, and the declaration of a fully franked interim dividend.\nNeuren Pharmaceuticals shares trade at A$19.89, with a 90 day share price return of 46.36% and a 30 day share price return of 10.50%. This comes despite a 7 day share price pullback of 11.72%, while the 5 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-reports-higher-sales-and-inter","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-reports-higher-sales-and-inter","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663445130","title":"NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2663445130","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663445130?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:22","pubTimestamp":1788088921,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) is back on investor radars after recent share price moves and a fresh look at its valuation profile. The stock closed at US$914.69, with an estimated intrinsic discount of 32.5%.\nOver the past few months NewMarket’s share price has gained momentum, with a 30 day share price return of 7.6% and a 90 day share price return of 14.7%. The 5 year total shareholder return of 193.4% highlights how strongly long term holders have been rewarded.\nSpot similar momentum stories by scanning...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VGFPF","BK7508","JOYT","DCF","DECU","BK4109","NEU","GXDW","NEU.AU","PMDE","FEBU","RGLO","BK7096","VOTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763421","title":"Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763421","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662763421?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:28","pubTimestamp":1787704117,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NEU.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662684667","title":"Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662684667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662684667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:27","pubTimestamp":1787700422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXQDJSS5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204730","title":"Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204730","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:10","pubTimestamp":1787616632,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said the European Commission gave marketing authorization for Daybu, or trofinetide, for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older to its exclusive global licensee for trofinetide, Acadia Pharmaceuticals, according to a Tuesday Australian bourse filing.Daybu is now authorized to be marketed in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, per the filing.Under the companies' license agreement, for Europe, Neuren is entitled to receive $35 million following first commercial sale, potential sales milestone payments of up to $170 million on achievement of escalating annual net sales thresholds, and tiered royalties from mid-teens to low-20s percentage of net sales.Acadia earlier said that a commercial launch in Germany is expected in the December quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662019942","title":"Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662019942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662019942?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:31","pubTimestamp":1787610678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUEC7XGBB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693426","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657693426?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:27","pubTimestamp":1786073273,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Friday.Mineral 260 : +10%, AU$0.80Light & Wonder CDI : +7%, AU$126.43Iluka Resources : +7%, AU$7.25Pilbara Minerals : +6%, AU$4.57Telix Pharmaceuticals : +6%, AU$15.89Liontown Resources : +6%, AU$1.14Predictive Discovery : +6%, AU$0.77West African Resources : +5%, AU$3.49James Hardie Industries : +5%, AU$42.78Neuren Pharmaceuticals : +4%, AU$22.52","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7504","BK7067","ILU.AU","BK7104","LTR.AU","BK7507","WAF.AU","TLX.AU","LNW.AU","BK7078","NEU.AU","JHX.AU","MI6.AU","BK7508","PDI.AU","PLS.AU","BK7095","BK7044","BK7506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657861486","title":"Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2657861486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657861486?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:42","pubTimestamp":1785994942,"startTime":"0","endTime":"0","summary":"In the second quarter of 2026, Neuren Pharmaceuticals reported record DAYBUE net sales of US$125 million, its highest quarterly result since launch, driven by strong uptake of the new DAYBUE STIX powder formulation in the US and supported by positive regulatory progress in Europe.\nThis sales performance led Neuren to upgrade its full-year 2026 royalty income projections, underscoring how formulation innovation and advancing European approvals are influencing its revenue outlook.\nWe’ll now...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-up-263-after-record-daybue","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-up-263-after-record-daybue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","NEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508098","title":"Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508098","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508098?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:52","pubTimestamp":1785981135,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals'  partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657677594","title":"Strong Partner Sales Propel Neuren Pharmaceuticals to Top of Australia Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2657677594","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657677594?lang=en_us&edition=fundamental","pubTime":"2026-08-05 11:34","pubTimestamp":1785900844,"startTime":"0","endTime":"0","summary":"BUZZ-Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark** Shares ofNeuren PharmaceuticalsNEU.AXrise as much as18.2% to A$22.00, theirhighest level since Oct 31, 2025** Co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4N4420AJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK4139","BK7096","LU2065171311.SGD","LU2065169927.USD","LU2065170008.USD","ACAD","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657593159","title":"Neuren Pharmaceuticals Limited-Record Q2 Daybue Net Sales of Us$125m, Cy26 Royalty Upgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=2657593159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657593159?lang=en_us&edition=fundamental","pubTime":"2026-08-05 07:52","pubTimestamp":1785887537,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUE5WT6FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655122638","title":"Earnings Flash (NEU) NewMarket Posts Q2 EPS of $14.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2655122638","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655122638?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:30","pubTimestamp":1785360623,"startTime":"0","endTime":"0","summary":"Earnings Flash (NEU) NewMarket Posts Q2 EPS of $14.54","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652258631","title":"NewMarket (NEU) Stock Looks Cheap Despite Its 182% Five Year Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2652258631","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652258631?lang=en_us&edition=fundamental","pubTime":"2026-07-19 03:22","pubTimestamp":1784402532,"startTime":"0","endTime":"0","summary":"NewMarket stock has delivered a strong 181.8% total return over the past 5 years, and today’s US$770.23 share price sits at a level where both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples still point to the shares trading below what the underlying cash flows may justify.\n\nA 181.8% return over 5 years suggests NewMarket has already rewarded long term holders, so any perceived discount now matters more for new capital being put to work.\nFuture cash generation may...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-stock-looks-cheap-despite-its-182-five-year-ru","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-stock-looks-cheap-despite-its-182-five-year-ru","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK4585","BK7508","BK4588","BK4109","NEU.AU","DCF","SPHQ","NEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651650194","title":"How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2651650194","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651650194?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:26","pubTimestamp":1784111213,"startTime":"0","endTime":"0","summary":"In June 2026, Mount Sinai’s Seaver Autism Center published research in Autism Research estimating Phelan-McDermid syndrome affects about 1 in 7,300 people, a much higher prevalence than earlier thought, in a study supported by CureSHANK and Neuren Pharmaceuticals. \nThis substantially larger patient population estimate highlights a potentially wider addressable market for ongoing precision medicine trials and future therapies targeting Phelan-McDermid syndrome. \nWe’ll now examine how this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-are-reacting-to-neuren-pharmaceuticals-asxneu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-are-reacting-to-neuren-pharmaceuticals-asxneu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","NEU.AU","BK4211","NEU","BK4109","ISBC","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649853671","title":"Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649853671","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649853671?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368355,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/growth-investors-industry-analysts-just-upgraded-their-neure","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/growth-investors-industry-analysts-just-upgraded-their-neure","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","ISBC","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648570303","title":"Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648570303","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648570303?lang=en_us&edition=fundamental","pubTime":"2026-07-02 15:45","pubTimestamp":1782978356,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) is back in focus after the European Medicines Agency's CHMP issued a positive opinion on its Rett syndrome treatment Daybue, clearing the path toward potential approval and European launch.\nSee our latest analysis for Neuren Pharmaceuticals.\nThat CHMP opinion has coincided with a sharp shift in sentiment toward Neuren Pharmaceuticals. The 7 day share price return of 36.82% and 90 day share price return of 46.72% contrast with a year to date share price decline...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-wins-chmp-backing-is-the-upsid","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-wins-chmp-backing-is-the-upsid","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHMP","BK4109","NEU.AU","BK4087","NEU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130284797","title":"Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue","url":"https://stock-news.laohu8.com/highlight/detail?id=1130284797","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130284797?lang=en_us&edition=fundamental","pubTime":"2026-06-30 08:02","pubTimestamp":1782777748,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}